DEF 14A: Creative Medical Technology Holdings Seeks Stockholder Approval for Share Increase and Warrant Exercise

Creative Medical Technology Holdings is holding a special meeting to seek stockholder approval for increasing authorized shares and approving the exercise of investor warrants.

Summary

• Creative Medical Technology Holdings is convening a special meeting of stockholders on December 19, 2024, to vote on two key proposals.
• The first proposal seeks approval to amend the company's Articles of Incorporation to increase the number of authorized common stock shares from 5,000,000 to 25,000,000.
• The second proposal requests approval for the full exercise of investor warrants to purchase 837,104 shares of common stock, issued in a private placement in October 2024.
• The Board of Directors unanimously recommends voting FOR both proposals.
• The record date for determining stockholders eligible to vote at the Special Meeting was October 23, 2024.
• The company has retained Okapi Partners LLC, a proxy solicitation firm, to solicit proxies for a fee of $8,000 plus expenses.

Sentiment

Score: 7

Explanation: The document is factual and procedural, outlining necessary steps for corporate actions. The sentiment is neutral to slightly positive as the company is proactively managing its capital structure.

Positives

• The Board believes increasing authorized shares provides flexibility for future capital raising, equity incentives, strategic relationships, and acquisitions.
• Approval of the warrant exercise would allow the company to fulfill its obligations to investors.
• The Board believes allowing the Investors to exercise the Investor Warrants Note in full is in the best interest of the Company and its stockholders because the Company is required to obtain the approval its stockholders to such exercise under its agreements with the Investors, and to repeatedly call stockholders meetings every 60 days until such stockholder approval is obtained.

Negatives

• Increasing authorized shares could dilute existing stockholders' ownership percentage.
• The exercise of investor warrants will dilute the ownership interest of existing stockholders.
• The sale of shares upon warrant exercise could adversely affect the market price of the company's common stock.
• Failure to approve the warrant exercise would require the company to hold additional stockholder meetings every 60 days, incurring substantial costs.

Risks

• The increase in authorized shares could have an anti-takeover effect, potentially making a change in control more difficult.
• The company's stock price could be negatively impacted by the issuance of new shares.
• Failure to secure stockholder approval for the warrant exercise will result in repeated meetings and associated expenses.

Future Outlook

The company intends to file articles of amendment to increase authorized shares promptly following stockholder approval and will register the resale of shares underlying the investor warrants.

Management Comments

• Timothy Warbington, Chief Executive Officer, encourages stockholders to vote as soon as possible.
• The Board of Directors has declared the amendment to be advisable and recommended that this proposal be presented to the Company's stockholders for approval.

Industry Context

Companies often seek to increase their authorized share capital to provide flexibility for future financing and strategic initiatives. Seeking stockholder approval for warrant exercises is a standard corporate governance practice to comply with Nasdaq listing rules.

Comparison to Industry Standards

• Increasing authorized shares is a common practice among publicly traded companies to facilitate future capital raises, employee stock options, and acquisitions.
• The specific percentage increase in authorized shares (from 5 million to 25 million) is substantial, suggesting the company anticipates significant future capital needs or strategic activity.
• Seeking stockholder approval for warrant exercises is standard practice to comply with Nasdaq Listing Rule 5635(d), which aims to protect shareholder interests by preventing excessive dilution without shareholder consent.
• The $8,000 fee plus expenses for proxy solicitation is within the typical range for similar services, although the actual cost will depend on the complexity of the solicitation and the level of shareholder engagement required.

Stakeholder Impact

• Approval of the proposals could impact shareholders through potential dilution.
• Employees may benefit from increased flexibility for equity incentives.
• The company's ability to pursue strategic relationships and acquisitions could be enhanced.

Next Steps

• Stockholders to vote on the proposals by December 18, 2024.
• The company expects to file articles of amendment promptly following approval of the Share Increase Proposal.
• The company will file a registration statement with the SEC to register the resale of the shares of Common Stock underlying the Investor Warrants under the Securities Act of 1933.
• The company will announce preliminary voting results at the Special Meeting.
• The company will disclose voting results on a Current Report on Form 8-K that we will file with the SEC within four business days after the Special Meeting.

Key Dates

Keywords

stockholders meeting, authorized shares, investor warrants, proxy statement, common stock, dilution, capital raising, corporate governance